C - Chemistry – Metallurgy – 07 – F
Patent
C - Chemistry, Metallurgy
07
F
C07F 9/38 (2006.01) A61K 31/66 (2006.01)
Patent
CA 2221417
Disclosed is a method for treating and preventing bone loss in patients by administering a formulation of anhydrous alendronate sodium. Also described is a pharmaceutical dosage form of said anhydrous alendronate sodium, being anhydrous 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, monosodium salt, in a pharmaceutically acceptable excipient.
La présente invention concerne un procédé permettant le traitement et la prévention de la déperdition osseuse chez certains patients. Ce procédé consiste en l'administration d'une formulation à base de sodium d'alendronate anhydre. L'invention concerne également une forme galénique de ce sodium d'alendronate anhydre, en l'occurrence, dans un excipient pharmacologiquement admis, un sel de monosodium à l'état anhydre de l'acide 4-amino-1-hydroxy-butylidène-1,1-biphosphonique.
Brenner Gerald S.
Oberholtzer Earl R. Jr.
Ostovic Drazen
Thies J. Eric
Merck & Co. Inc.
Merck Sharp & Dohme Corp.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Anhydrous alendronate monosodium salt formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anhydrous alendronate monosodium salt formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anhydrous alendronate monosodium salt formulations will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1402640